• Enlitic signs binding MoU with GE HealthCare for up to A$50m revenue over 5 years
• Enlitic secures A$10m capital raise from new and existing institutional investors
• Funds to be used for R&D, sales, marketing, and other strategic initiatives

Enlitic, Inc. (ASX: ENL) has signed a binding memorandum of understanding (MOU) with GE Precision Healthcare, LLC. ('GEHC' or 'GE HealthCare') under which Enlitic's wholly owned subsidiary Laitek Inc. will work to deliver between US$3-6m per year (A$5-10m) of annual migration capacity to GEHC for the next 5 years, representing a total revenue opportunity of up to A$50 million. GEHC has also agreed to prepay US$2 million for Laitek's migration services. The arrangements under the MOU are conditional on Enlitic securing a minimum of A$10 million in funding from external sources. Enlitic has received firm commitments from new and existing institutional and sophisticated investors to raise A$10 million via a two-tranche placement. Tranche one will raise ~A$5.8 million, while tranche two of ~A$4.2 million is subject to shareholder approval.The funds raised will be used for research and development, quality and regulatory, strategic development, sales and marketing, customer service, corporate expenses, and working capital. Enlitic still anticipates achieving operational cashflow break-even by the end of CY25.

Enlitic has signed an MOU with GE HealthCare that represents a revenue opportunity of up to A$50 million over the next 5 years.

Enlitic remains committed to partnering with GE HealthCare and other clients to drive long-term value and deliver better outcomes for healthcare systems around the world.